NRx Pharmaceuticals Appoints Mike Taylor to Board of Directors

On January 15, 2025, NRx Pharmaceuticals, Inc. appointed Mike Taylor as a Class I member of its Board of Directors. Taylor, aged 50, brings with him 25 years of experience in the global credit business, specializing in special situations and capital formation. Previously, he served as a Partner at the Adi Dassler International Family office wealth advisory firm and held positions at Oppenheimer & Co. Inc. and Stone & Youngberg LLC. Taylor, who holds a Bachelor of Science degree in Economics & International Relations from the London School of Economics, will occupy the seat vacated by Janet Rehnquist.

This appointment comes in light of a recent investment agreement between NRx Pharmaceuticals and JGS Holdings LLC, a Wyoming limited liability company. As per the agreement, JGS Holdings LLC intends to purchase $25.0 million in shares of HOPE Therapeutics, Inc.’s Series A Preferred Stock convertible into one-third of all fully diluted outstanding equity and 730,000 shares of NRx Pharmaceuticals’ common stock at a purchase price of $2.0 million. Mike Taylor will serve on the Board until the next annual meeting of shareholders or until his successor is elected and qualified.

In another development, the company announced on January 21, 2025, that it has regained compliance with the minimum market value of listed securities requirement under NASDAQ Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market. A press release detailing this compliance is available on the company’s Current Report on Form 8-K.

Aside from the disclosed transactions, NRx Pharmaceuticals stated that there are no additional related party transactions with Mr. Taylor that necessitate disclosure under Regulation S-K’s Item 404(a) or any further arrangements associated with his appointment to the Board.

The press release regarding the compliance update with Nasdaq can be accessed on the attached Exhibit 99.1 to this Form 8-K filing.

No other financial statements were provided in the filing.

The signing of the report was completed by Jonathan Javitt, NRx Pharmaceuticals’ Interim Chief Executive Officer, on January 22, 2025.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NRx Pharmaceuticals’s 8K filing here.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.